Major Pharmaceuticals Recalls Levothyroxine Sodium Tablets Over Subpotency
Major Pharmaceuticals is recalling Levothyroxine Sodium Tablets, 112 mcg, lot N02203, due to subpotent drug concerns. The recall affects nationwide U.S. distribution and was initiated voluntarily by the firm.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class II recall of a subpotent prescription drug. Per the rubric, FDA Class II recalls with potential for serious health consequences are classified as Severe (score 4).
Plain-English summary
Major Pharmaceuticals is recalling Levothyroxine Sodium Tablets, USP, 112 mcg (0.0112 mg), packaged in 100-tablet cartons (10 x 10 unit dose blisters), NDC 0904-6954-61. The recall covers lot number N02203 with an expiration date of September 2026. The product was distributed nationwide in the United States.
The recalled product
- Product
- LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM)
- Brand
- LEVOTHYROXINE SODIUM
- Manufacturer
- Major Pharmaceuticals
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: N02203
- Exp. Date 09/2026
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 12 recalled by Major Pharmaceuticals under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 12 products in this recall →Related recalls
Same brand · LEVOTHYROXINE SODIUM
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
Same manufacturer · Major Pharmaceuticals
See all →- HighLevothyroxine Sodium Tablets Recalled for Subpotency by Major Pharmaceuticals
FDA (Drugs) · 2026-07-29
- SevereMajor Pharmaceuticals Recalls Levothyroxine Sodium Tablets Over Subpotency
FDA (Drugs) · 2026-07-29
- SevereLevothyroxine Sodium Tablets Recalled for Subpotency Nationwide
FDA (Drugs) · 2026-07-29
- HighLevothyroxine Sodium Tablets Recalled Due to Subpotent Drug Concerns
FDA (Drugs) · 2026-07-29
- SevereLevothyroxine Sodium Tablets Recalled for Subpotency
FDA (Drugs) · 2026-07-29
Same hazard · subpotent drug
See all →- SeverePfizer Recalls Levoxyl Tablets Due to Subpotent Drug Levels
FDA (Drugs) · 2026-10-28
- LowImprimisRx Recalls Subpotent Povidone Iodine and Proparacaine Ophthalmic Solution
FDA (Drugs) · 2026-09-16
- ModerateAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
Similar recalls
- HighLevothyroxine Sodium Tablets Recalled Due to Potency Failures
FDA (Drugs) · 2024-12-18
- HighLevothyroxine Sodium Tablets Recalled Due to Subpotency Nationwide
FDA (Drugs) · 2024-12-11
- HighMacleods levothyroxine 150 microgram tablets recalled as a subpotent drug
FDA (Drugs) · 2026-04-01
- HighLevothyroxine Sodium Tablets Recalled for Subpotent and Superpotent Content
FDA (Drugs) · 2024-12-18
- HighLevothyroxine Sodium 100 mcg Tablets Recalled for Potency Deviations Nationwide
FDA (Drugs) · 2024-12-18
- HighLevothyroxine Sodium Tablets Recalled Nationwide for Potency Variance
FDA (Drugs) · 2024-12-18